Merck Serono, a division of German's Merck KGaA, has announced a new five-year clinical development agreement with Quintiles. This strategic collaboration is the first-of-its-kind between a ...

EMD Serono, the American drug development arm of Germany’s Merck KGaA, plans to move its headquarters from the South Shore town of Rockland to Boston’s Seaport district next summer.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

In 2003 Merck Serono, a world leader in the field of biotechnology engaged PDD to design an auto-injector for its Growth Hormone (GH) therapy product Saizen®. In what was a saturated and static market ...

Are you a print subscriber? Activate your account. By Garett Sloane - 2 hours 35 min ago By Gillian Follett - 2 hours 35 min ago By E.J. Schultz - 2 hours 35 min ago By Jack Neff - 2 hours 35 min ...

Oct 17 (Reuters) - German science and technology group Merck (MRCG.DE), opens new tab is open to more acquisitions for its Life Science business after announcing in May it would buy Mirus Bio for ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Investors in Merck & Co Inc (Symbol: MRK) saw new options begin trading today, for the February 2025 expiration. One of the key inputs that goes into the price an option buyer is willing to pay ...

Anyone crafting a bull case for the pharmaceutical giant Merck (NYSE: MRK) should include Keytruda as the company's best asset. The cancer drug has been Merck's top-selling medicine and its ...

Merck KGaA said it’s seeing the beginning of a post-Covid pandemic rebound in life sciences as it reaffirmed the group’s sales and profit guidance for the full year. The German science and ...

Merck (MRK) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.

(RTTNews) - Merck & Co., Inc. (MRK) announced the positive results from the Phase 2b/3 clinical trial (MK-1654-004) evaluating clesrovimab, the company's investigational prophylactic monoclonal ...